scholarly journals Breaktrough drug combination for Congenital Junctional Ectopic Tachycardia: a pediatric case report.

2021 ◽  
Author(s):  
Giovanni Di Marco ◽  
Angelica De Nigris ◽  
Giangiacomo Di Nardo
Keyword(s):  
Case Report ◽  
Drug Combination ◽  
Therapeutic Strategy ◽  
Drug Combinations ◽  
Suboptimal Control ◽  
Antiarrhythmic Agents ◽  
Pediatric Case ◽  
Junctional Ectopic Tachycardia ◽  
New Drug ◽  
Conventional Drug

Introduction: Congenital Junctional Ectopic Tachycardia (JET) is a rare tachyarrhythmia that remains difficult to manage with suboptimal control in the majority of cases. Methods: Here, we report the successful use of Ivabradine in combination with Flecainide for the therapy of congenital JET resistant to multiple antiarrhythmic agents. Results: This new drug combination was effective in completely suppressing JET . Conclusion: Ivabradine in combination with Flecainide may be considered a new therapeutic strategy of congenital JET with satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations.

scholarly journals Ivabradine–Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review

2021 ◽  
Vol 13 (4) ◽  
pp. 624-631
Author(s):  
Giovanni Maria Di Marco ◽  
Angelica De Nigris ◽  
Angela Pepe ◽  
Annamaria Pagano ◽  
Giangiacomo Di Nardo ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Drug Combination ◽  
Therapeutic Strategy ◽  
Suboptimal Control ◽  
Antiarrhythmic Agents ◽  
Junctional Ectopic Tachycardia ◽  
Literature Research ◽  
Conventional Drug ◽  
Breakthrough Drug

Congenital junctional ectopic tachycardia (CJET) is a rare tachyarrhythmia that remains difficult to manage, with suboptimal control in most cases. Here, we report literature research on the use of ivabradine in the treatment of pediatric junctional ectopic tachycardia (JET), both congenital and postoperative, and describe the successful use of ivabradine–flecainide association for CJET therapy resistant to other antiarrhythmic agents. This new drug combination was effective in completely suppressing JET. Ivabradine–flecainide combination may be considered a new therapeutic strategy of CJET with a satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations.

scholarly journals Green tea-induced anaphylaxis: The first pediatric case report

2021 ◽  
Author(s):  
Naoki Kajita ◽  
Satoshi Miyama ◽  
Kazue Kinoshita ◽  
Koichi Yoshida ◽  
Masami Narita
Keyword(s):  
Case Report ◽  
Green Tea ◽  
Pediatric Case

scholarly journals Biomolecular Network-Based Synergistic Drug Combination Discovery

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Xiangyi Li ◽  
Guangrong Qin ◽  
Qingmin Yang ◽  
Lanming Chen ◽  
Lu Xie
Keyword(s):  
Drug Combination ◽  
Complex Disease ◽  
Recent Decade ◽  
Drug Combinations ◽  
Network Medicine ◽  
Disease Therapy ◽  
Biomolecular Network ◽  
Disease Related Genes ◽  
Disease Specific ◽  
Synergistic Drug Combinations

Drug combination is a powerful and promising approach for complex disease therapy such as cancer and cardiovascular disease. However, the number of synergistic drug combinations approved by the Food and Drug Administration is very small. To bridge the gap between urgent need and low yield, researchers have constructed various models to identify synergistic drug combinations. Among these models, biomolecular network-based model is outstanding because of its ability to reflect and illustrate the relationships among drugs, disease-related genes, therapeutic targets, and disease-specific signaling pathways as a system. In this review, we analyzed and classified models for synergistic drug combination prediction in recent decade according to their respective algorithms. Besides, we collected useful resources including databases and analysis tools for synergistic drug combination prediction. It should provide a quick resource for computational biologists who work with network medicine or synergistic drug combination designing.

Pediatric Case Report: CPT1A Arctic Variant

2021 ◽  
Vol 35 (2) ◽  
pp. 231-234
Author(s):  
Sarah E. Evans
Keyword(s):  
Case Report ◽  
Pediatric Case

scholarly journals Using Yeast Synthetic Lethality To Inform Drug Combination for Malaria

2018 ◽  
Vol 62 (4) ◽  
Author(s):  
Suvitha Subramaniam ◽  
Christoph D. Schmid ◽  
Xue Li Guan ◽  
Pascal Mäser
Keyword(s):  
Plasmodium Falciparum ◽  
Drug Combination ◽  
Synthetic Lethality ◽  
Drug Combinations ◽  
Synthetic Lethal Interaction ◽  
Content Type ◽  
Synthetic Lethal ◽  
Gene Pairs ◽  
Phosphatidylinositol 4

ABSTRACT Combinatorial chemotherapy is necessary for the treatment of malaria. However, finding a suitable partner drug for a new candidate is challenging. Here we develop an algorithm that identifies all of the gene pairs of Plasmodium falciparum that possess orthologues in yeast that have a synthetic lethal interaction but are absent in humans. This suggests new options for drug combinations, particularly for inhibitors of targets such as P. falciparum calcineurin, cation ATPase 4, or phosphatidylinositol 4-kinase.

scholarly journals BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone

2021 ◽  
Vol 254-255 ◽  
pp. 70-74
Author(s):  
Yvonne Lisa Behrens ◽  
Andrea Schienke ◽  
Claudia Davenport ◽  
Jana Lentes ◽  
Marcel Tauscher ◽  
...  
Keyword(s):  
Case Report ◽  
Blast Crisis ◽  
Pediatric Case

P011 Just a spoonful of sugar helps the medicine go down: L-arginine pill related esophageal ulcer, the first pediatric case report

2018 ◽  
Vol 50 (4) ◽  
pp. e363
Author(s):  
P. Gaio ◽  
L. Bosa ◽  
S. Rossin ◽  
V. Buccella ◽  
L. Nai Fovino ◽  
...  
Keyword(s):  
Case Report ◽  
Esophageal Ulcer ◽  
Pediatric Case
Sign in / Sign up

Export Citation Format

Share Document